Cancer immunotherapy has emerged as an effective treatment option for a variety of malignancies. The fusion of new therapeutic options, imaging techniques, and biomarker development is driving extraordinary advancement in the field of healthcare. With these exciting new possibilities comes the responsibility to accurately and precisely measure their effects.

At DICE, we strive to deliver the most appropriate selection of immune-related imaging interpretation criteria to best fit your trial's methodology and maximize the quality of your trial imaging endpoints.

Our expert team will seamlessly work across multiple interpretation criteria combining the well-established RECIST-based guidelines with the novel immune-related evaluation criteria to evaluate early and rapid changes, detect and differentiate pseudo-progression versus true tumor progression.

We work in close collaboration with our skilled Statistics team should you request the development and validation of new or modified, trial-specific immune interpretation criteria or disease biomarkers.